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Abstract
Background: Plasma amyloid-β (Aβ) levels are increasingly studied as a potential accessible marker of cognitive
impairment and dementia. However, it remains underexplored whether plasma Aβ levels including the novel Aβ
peptide 1–38 (Aβ1–38) relate to preclinical markers of neurodegeneration and risk of dementia. We investigated the
association of plasma Aβ1–38, Aβ1–40, and Aβ1–42 levels with imaging markers of neurodegeneration and risk of
dementia in a prospective population-based study.
Methods: We analyzed plasma Aβ levels in 458 individuals from the Rotterdam Study. Brain volumes, including
gray matter, white matter, and hippocampus, were computed on the basis of 1.5-T magnetic resonance imaging
(MRI). Dementia and its subtypes were defined on the basis of internationally accepted criteria.
Results: A total of 458 individuals (mean age, 67.8 ± 7.7 yr; 232 [50.7%] women) with baseline MRI scans and incident
dementia were included. The mean ± SD values of Aβ1–38, Aβ1–40, and Aβ1–42 (in pg/ml) were 19.4 ± 4.3, 186.1 ± 35.9,
and 56.3 ± 6.2, respectively, at baseline. Lower plasma Aβ1–42 levels were associated with smaller hippocampal volume
(mean difference in hippocampal volume per SD decrease in Aβ1–42 levels, − 0.13; 95% CI, − 0.23 to − 0.04; p = 0.007).
After a mean follow-up of 14.8 years (SD, 4.9; range, 4.1–23.5 yr), 79 persons developed dementia, 64 of whom were
diagnosed with Alzheimer’s disease (AD). Lower levels of Aβ1–38 and Aβ1–42 were associated with increased risk of
dementia, specifically AD (HR for AD per SD decrease in Aβ1–38 levels, 1.39; 95% CI, 1.00–2.16; HR for AD per SD
decrease in Aβ1–42 levels, 1.35; 95% CI, 1.05–1.75) after adjustment for age, sex, education, cardiovascular risk factors,
apolipoprotein E ε4 allele carrier status, and other Aβ isoforms.
Conclusions: Our results show that lower plasma Aβ levels were associated with risk of dementia and incident AD.
Moreover, lower plasma Aβ1–42 levels were related to smaller hippocampal volume. These results suggest that plasma
Aβ1–38 and Aβ1–42 maybe useful biomarkers for identification of individuals at risk of dementia.
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Background
Dementia due to Alzheimer’s disease (AD), constituting
up to 70% of all dementias, is characterized by deposition
of amyloid plaques and neurofibrillary tangles in the brain
parenchyma [1]. Amyloid-β (Aβ) 1–40 (Aβ1–40) and Aβ1–42
peptides derived from amyloid precursor protein are
present in these parenchymal plaques, and it is hypothe-
sized that Aβ peptide abnormalities begin early in the neu-
rodegenerative pathological cascade [2, 3]. According to
this amyloid cascade hypothesis, an imbalance between the
production and clearance of the Aβ peptides, especially the
Aβ1–42 isoform, leads to their aggregation in the cortical
tissue and vessels [3]. This Aβ deposition in the brain sub-
sequently affects plasma concentrations, thus suggesting
that circulating levels of Aβ could potentially be used as
markers of disease risk [4].
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Aβ1–40 and Aβ1–42 peptides are the two most studied AD
biomarkers, which can be measured in plasma through
minimally invasive techniques and thus can feasibly be de-
termined in large samples. Several large community-based
studies have reported on the association of high plasma
Aβ1–40 and Aβ1–42 levels and lower Aβ1–42/Aβ1–40 ratios at
baseline with risk of dementia and reduced cognitive meas-
ure scores [5–7]. Two studies have shown a link between
higher levels of Aβ1–42 but not Aβ1–40 with risk of AD [8,
9]. Conversely, some studies reported an association of
increased concentrations of Aβ1–42 and Aβ1–40 levels and
higher Aβ1–42/Aβ1–40 ratio with reduced risk of dementia
[10, 11]. Longitudinal studies with repeated measurements
of Aβ have shown that individuals in preclinical stages of
the disease [12] and persons with newly diagnosed AD [6]
showed significant reductions in plasma Aβ1–42 concentra-
tions over time. Though most of the study results are in-
consistent, they nevertheless do suggest that plasma Aβ
levels may be differentially associated with the risk for AD,
possibly reflective of the stage of the disease and the com-
plex pattern of production and clearance from the brain
[4]. Limited data also suggest that increased circulating
levels of Aβ1–40 and Aβ1–42 may induce cerebral atrophy,
detected on magnetic resonance imaging (MRI) stud-
ies as cortical thinning in asymptomatic elderly
persons through mechanisms such as synaptic deficits
and neuronal loss [13-15] . More studies of a general
population are needed to investigate the relationship
between Aβ and markers of neurodegeneration as
well as risk of dementia to further comprehend the
underlying mechanisms in a subclinical phase.
Besides Aβ1–40 and Aβ1–42 peptides, which have been in-
vestigated extensively, another isoform—Aβ1–38—is of
interest because it is reported to be elevated in the cerebro-
spinal fluid (CSF) of patients with sporadic AD [16]. More-
over, it is suggested to be a sensitive and specific marker
for diagnosing AD over the range of other non-AD demen-
tias, and subsequent studies confirmed the suitability of
Aβ1–38 as an additional biomarker for differential diagnosis
of dementia [17, 18]. Despite this ongoing research, little is
known regarding whether plasma Aβ levels, including the
novel Aβ1–38, are associated with preclinical markers of
neurodegeneration, such as gray matter, white matter, and
hippocampal atrophy, and the risk of dementia in a large
population-based setting. We examined the association of
plasma Aβ1–38, Aβ1–40, and Aβ1–42 levels with neurodegen-
erative markers and risk of dementia in a subsample of the
Rotterdam Study.
Methods
Study population
The Rotterdam Study is a population-based prospective
cohort study of middle-aged and elderly persons living in
the Ommoord district in the city of Rotterdam, the
Netherlands. All participants in this study undergo reex-
amination every 3–4 years and are being followed continu-
ously for events, including occurrence of dementia. This
study is embedded within the first cohort, which was initi-
ated in 1990 with 7983 participants at baseline (aged ≥
55 yr). Persons were randomly selected (n = 563) during
the second visit of the first cohort (1995–1996) and were
invited to undergo neuroimaging [19]. Blood samples of
the same individuals were drawn in the 1998 and 1999.
After individuals with insufficient plasma (n = 22), no MRI
scans (n = 73), and prevalent dementia (n = 10) were re-
moved, the final sample size consisted of 458 persons [20].
Plasma assessment
Blood samples were drawn into ethylenediaminetetraacetic
acid (EDTA) tubes for plasma collection. After centrifuga-
tion (2500 × g, + 4 °C for 20 min), plasma samples were
stored at − 80 °C within 60 minutes of collection. Plasma
levels of Aβ1–38, Aβ1–40, and Aβ1–42 were quantified by
EUROIMMUN β-Amyloid 1–38, 1–42, and 1–40 plasma
enzyme-linked immunosorbent assays (EUROIMMUN,
Lübeck, Germany), which have been validated and
described in more detail previously [21, 22]. For quality
control (QC) purposes, QC samples were produced by
pooling of EDTA plasma samples from individual partici-
pants. After aliquoting, samples were stored at − 80 °C.
The samples were coded QC1, QC2, QC8, QC9, and
QC10 and were used in the three plasma amyloid assays.
QC in the three assays was ± 2 SD of each amyloid concen-
tration (in pg/ml) across study participants, with the ranges
of concentration values detectable being 5.9–18.7 pg/ml
for Aβ1–38, 67.6–161.8 pg/ml for Aβ1–40, and 46.6–55.6 pg/
ml for Aβ1–42. The average coefficients of variation of
measurement of Aβ1–38, Aβ1–40, and Aβ1–42 in QC plasma
samples during the study were 11.04%, 5.72%, and 8.70%,
respectively [22].
Brain imaging
Brain MRI was performed using a 1.5-T MRI system
(VISION MR; Siemens AG, Erlangen, Germany) to obtain
T1-weighted, proton density, T2-weighted, and
high-resolution inversion recovery double-contrast
three-dimensional half-Fourier-acquired single-shot turbo
spin echo (HASTE) sequences [23]. Image preprocessing
and the tissue classification algorithm have been described
elsewhere [23]. Briefly, the k-nearest neighbors brain tissue
classifier technique was used to classify voxels into CSF,
gray matter, normal white matter, and white matter hyper-
intensities. Intracranial volume was the sum of the CSF,
gray matter, normal white matter, and white matter hyper-
intensities. We used a validated nonrigid registration algo-
rithm to map brain regions to the template scan.
Hippocampal volumes were manually outlined on coronal
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HASTE sequences perpendicular to the long axis of the
hippocampus [24].
Assessment of dementia
Participants were screened for dementia at baseline and at
follow-up examinations [20]. Screening was performed
using the Mini Mental State Examination (MMSE) and the
Geriatric Mental State Schedule (GMS) organic level. Indi-
viduals with screen-positive results (MMSE < 26 or GMS
organic level > 0) subsequently underwent an examination
and informant interview with the Cambridge Examination
for Mental Disorders of the Elderly. Additionally, the whole
cohort was continuously monitored for dementia through
computerized linkage of the study database and digitized
medical records of general practitioners and the Regional
Institute for Outpatient Mental Health Care. When
required and available, neuroimaging was used to facilitate
dementia diagnosis. A consensus panel led by a consultant
neurologist established the final diagnosis according to
standard criteria for dementia (Diagnostic and Statistical
Manual of Mental Disorders, Third Edition–Revised). The
diagnosis of AD was made using the National Institute of
Neurological and Communicative Disorders and
Stroke-Alzheimer’s Disease and Related Disorders Associ-
ation [25] and National Institute of Neurological Disorders
and Stroke-Association Internationale pour la Recherché
et l’Enseignement en Neurosciences criteria for vascular
dementia [26]. The first cohort was followed for dementia
until 15 years (based on maximum follow-up) after
baseline examination (i.e., January 2015). Follow-up for
dementia was complete for 99.5% of potential person-years
in this cohort.
Covariate assessment
Data on demographics and medical history were recorded
on the same day of dementia screening. Blood pressure
was measured in two readings using a random zero sphyg-
momanometer in a sitting position, and the mean of both
measurements was calculated. Mean arterial blood pres-
sure was calculated as two-thirds of the diastolic blood
pressure plus one-third of the systolic blood pressure.
Serum total cholesterol levels were measured using an au-
tomated enzymatic procedure. Diabetes mellitus was de-
fined as fasting blood glucose ≥ 7 mmol/L or receiving
treatment for diabetes. Smoking was categorized into ever
versus never smokers. Education was treated as the num-
ber of years of formal education. Apolipoprotein E
(APOE) genotype was determined using PCRs on coded
DNA samples. Distribution of APOE genotype and allele
frequencies were in Hardy-Weinberg equilibrium.
APOE-ε4 carrier status was defined by the presence of at
least one ε4 allele.
Statistical analysis
Plasma Aβ levels and brain tissue volumes were standard-
ized (by subtracting each variable by population mean di-
vided by SD). Plasma Aβ levels were expressed as per-SD
decrease. The Aβ1–40/Aβ1–42 ratio was calculated using
raw values of Aβ1–40 and Aβ1–42 levels. We first per-
formed linear regression models to determine the associ-
ation between Aβ levels and brain tissue volumes (total
brain volumes, white matter volume, gray matter volume,
and hippocampal volume). The models were adjusted for
age, sex, intracranial volume, mean arterial blood pressure,
total cholesterol, diabetes, smoking, and APOE-ε4 carrier
status. We tested the independent effects of Aβ levels with
brain tissue volumes by adding all three isoforms together
in the regression models.
Using Cox proportional hazards models, we calculated
HRs with corresponding 95% CIs for dementia and its sub-
types with per-SD decrease in Aβ level. Participants were
censored within the follow-up period at date of event diag-
nosis, death, or loss to follow-up, whichever came first.
The proportional hazards assumption was tested by adding
the interaction terms of Aβ1–38, Aβ1–40, Aβ1–42, and Aβ1–40/
Aβ1–42 ratio with follow-up time in different models. All
Cox proportional hazards models were initially adjusted for
age, sex, and education and subsequently for mean arterial
blood pressure, total cholesterol, diabetes, smoking,
APOE-ε4 carrier status, and the other Aβ isoforms using a
similar approach to the one described above. We also
investigated whether the association between plasma Aβ
and dementia was different in carriers and noncarriers of
the APOE-ε4 allele. The level of significance was set to 5%,
and all tests were two-sided. Statistical analyses were
performed using IBM SPSS Statistics version 24 software
(IBM, Armonk, NY, USA).
Results
Baseline characteristics of the participants are shown in
Table 1. The mean age of the participants was 67.8 ±
7.7 years, and 232 (50.7%) were women. Diabetes was
present in 55 (12.1%) of the study population, whereas the
frequency of ever smokers was 317 (69.7%). Almost 30%
(n = 137) persons were APOE-ε4 carriers. The mean ± SD
values of Aβ1–38, Aβ1–40, and Aβ1–42 were 19.4 ± 4.3,
186.1 ± 35.9, and 56.3 ± 6.2, whereas for white matter vol-
ume, gray matter volume, and hippocampal volume, the
respective values were 354.1 ± 85.4, 522.7 ± 55.8, and 6.4 ±
0.9. The correlation between Aβ1–38 and Aβ1–40 was 0.81
(Pearson’s correlation coefficient, R); between Aβ1–38 and
Aβ1–42, R = 0.24, and between Aβ1–40 and Aβ1–42, R = 0.25.
Table 2 shows the cross-sectional analysis between Aβ
levels and brain tissue volumes adjusted for age, sex, vascu-
lar risk factors, APOE-ε4 carrier status, intracranial
volume, and other Aβ isoforms, when appropriate. Lower
Aβ1–38, Aβ1–40, and Aβ1–42 levels and lower Aβ1–40/Aβ1–42
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ratio were not associated with total brain, gray, and white
matter volumes. A significant association was observed be-
tween lower plasma Aβ1–42 levels and smaller hippocampal
volume (mean difference in hippocampal volume per SD
decrease in Aβ1–42 levels, − 0.13; 95% CI, − 0.23 to − 0.04;
p = 0.007).
During a mean follow-up of 14.8 years (SD, 4.9; range,
4.1–23.5 yr), 241 individuals died. In the same follow-up,
79 persons developed dementia. Of these 79 individuals
with dementia, 64 were diagnosed with AD and 15 with
vascular dementia. The interaction terms of Aβ levels
with follow-up time in all models were nonsignificant (p
value for interaction between Aβ1–38 and time, p = 0.832;
between Aβ1–40 and time, p = 0.820; between Aβ1–42 and
time, p = 0.998; and between Aβ1–40/Aβ1–42 ratio and
time, p = 0.984). In the multivariable analysis, lower
levels of Aβ1–38 and Aβ1–42 were associated with in-
creased risk of dementia (HR for dementia per SD de-
crease in Aβ1–38, 1.33; 95% CI, 1.01–1.89; HR for
dementia per SD decrease in Aβ1–42, 1.27; 95% CI, 1.02–
1.58) (Table 3). No association was observed between
Aβ1–40 and Aβ1–40/Aβ1–42 ratio and dementia. When the
analysis was performed separately for dementia subtypes,
lower levels of Aβ1–38 and Aβ1–42 were associated with
increased risk of AD (HR for AD per SD decrease in
Aβ1–38, 1.39; 95% CI, 1.00–2.16; HR for AD per SD de-
crease in Aβ1–42, 1.35; 95% CI, 1.05–1.75). The HRs for
AD and vascular dementia were closely similar but
Table 1 Baseline characteristics of the study population
Variables Subsample of Rotterdam Study
(n = 458)
Demographic and vascular risk factors
Age, yr, mean (SD) 67.8 (7.7)
Women, n (%) 232 (50.7)
Education, yr, mean (SD) 10.7 (3.4)
Mean arterial blood pressure, mmHg, mean (SD) 96.5 (12.7)
Total cholesterol, mmol/L, mean (SD) 5.7 (0.93)
Diabetes mellitus, n (%) 55 (12.1)
Smoker, ever, n (%) 317 (69.7)
APOE-ε4 carriers, n (%) 137 (30)
Plasma levels of Aβ isoforms, pg/ml, mean (SD)
Aβ1–38 19.4 (4.3)
Aβ1–40 186.1 (35.9)
Aβ1–42 56.3 (6.2)
MRI markers, ml, mean (SD)
White matter volume 354.1 (85.4)
Gray matter volume 522.7 (55.8)
Intracranial volume 1126.2 (113.9)
Hippocampus volume 6.4 (0.9)
Abbreviations: , APOE Apolipoprotein, Aβ Amyloid-β, MRI Magnetic resonance imaging
Table 2 Association of amyloid-β levels with neurodegenerative markers
Plasma Aβ levels
(per SD decrease)
Total brain volume, mean
difference (95% CI),a
p value
Total gray matter volume,
mean difference (95% CI),a
p value
Total white matter volume,
mean difference (95% CI),a
p value
Total hippocampal volume,
mean difference (95% CI),a
p value
Aβ1–38 0.03 (− 0.03; 0.08),
p = 0.362
0.02 (− 0.10; 0.15),
p = 0.715
0.01 (− 0.09; 0.12),
p = 0.819
0.04 (− 0.11; 0.19),
p = 0.582
Aβ1–40 − 0.04 (− 0.09; 0.02),
p = 0.171
− 0.08 (− 0.21; 0.06),
p = 0.248
0.01 (− 0.11; 0.12),
p = 0.912
− 0.01 (− 0.17; 0.14),
p = 0.869
Aβ1–42 0.00 (− 0.03; 0.04),
p = 0.812
− 0.06 (− 0.14; 0.03),
p = 0.174
0.04 (− 0.03; 0.12),
p = 0.251
− 0.13 (− 0.23; − 0.04),
p = 0.007
Aβ1–40/Aβ1–42 ratio 0.03 (− 0.02; 0.09)
p = 0.231
0.06 (− 0.07; 0.19),
p = 0.380
−0.00 (− 0.11; 0.11)
p = 0.998
−0.10 (− 0.25; 0.05),
p = 0.194
Abbreviations: Aβ amyloid-β, SD standard deviation, CI confidence interval
a Adjusted for age, sex, mean arterial blood pressure, total cholesterol, diabetes, apolipoprotein ε4 carrier status, smoking, intracranial volume and other Aβ levels
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insignificant in cases of vascular dementia (Table 3). The
association between lower levels of Aβ and risk of
dementia among APOE-ε4 carriers and noncarriers ap-
peared similar, such that lower levels of Aβ1–38, Aβ1–40,
and Aβ1–42 were associated with increased risk of
dementia in both strata. A stronger association was
observed for Aβ1–38 with increased risk of dementia
among APOE-ε4 carriers (HR for dementia per SD
decrease in Aβ1–38, 1.58; 95% CI, 1.01–2.89), whereas for
Aβ1–42, this association was observed only among
APOE-ε4 noncarriers (HR for dementia per SD decrease
in Aβ1–42, 1.47; 95% CI, 1.09–1.99) (Table 4).
Discussion
In this study, we showed that lower levels of plasma Aβ
were not associated with preclinical markers of neurode-
generation (i.e., total gray matter and white matter
volumes), except for Aβ1–42, which was associated with
smaller hippocampal volume in elderly individuals. Indi-
viduals with lower levels of Aβ1–38 and Aβ1–42 had an
independent increased risk of dementia, specifically AD.
These findings suggest that Aβ1–38 and Aβ1–42 may be
involved in different pathways leading to dementia.
Previous research has shown that higher plasma Aβ
levels (1–40 and 1–42 peptides) at baseline were associated
with cognitive dysfunction and faster cognitive decline,
regardless of dementia status at follow-up, supporting the
notion that plasma Aβ may induce a variety of brain path-
ologies (including cortical atrophy) earlier in life [27]. A
recent study consisting of 100 participants also reported
that higher plasma Aβ1–42 levels were associated with
thinner temporal cortex in cognitively normal elderly per-
sons [13]. However, apart from the latter study, no studies
have yet combined the structural brain changes with
plasma Aβ levels to assess the differences in cognitively
normal elderly individuals. Moreover, the effects of novel
Aβ1–38 in addition to Aβ1–40 and 1–42 on cerebral atrophy
and whether it is an important fluid biomarker for neuro-
degeneration and dementia has not been explored previ-
ously. Contrary to what we expected, our findings showed
that lower plasma Aβ levels (including Aβ1–38) were not re-
lated to brain tissue volumes, except for hippocampal vol-
ume, where a significant association was observed between
lower Aβ1–42 levels and smaller hippocampal volume in the
elderly. The possible reason for the lack of association
between Aβ1–38 and brain atrophy could be that plasma
Aβ1–38 levels may reflect vascular disease in the brain
rather than neurodegeneration. On one hand, this is
supported by our previous study in which we showed that
Aβ1–38 reflected microvascular damage in the brain and
possibly induced adverse changes by inflammation, imbal-
ance of oxygen free radicals, and apoptosis [22]. On the
other hand, the association between Aβ1–42 and the
hippocampus in the present study supports the notion
that as Aβ1–42 starts to deposit in the brain after the age
of 60 years, lower plasma Aβ levels that follow this depos-
ition relate to hippocampal atrophy. A recent study has
shown that accumulation of Aβ and tau pathologies in the
brain were related to a decrease in hippocampal volume,
including its critical subcompartments (i.e., CA1 and
subiculum) in the earliest stages of AD prodromes [28].
Moreover, another study with healthy control individuals
Table 3 Association of amyloid-β levels with incident dementia and its subtypes
Plasma Aβ levels (per SD decrease) Incident dementia (n = 79)
HR (95% CI)a
Alzheimer’s dementia (n = 64)
HR (95% CI)a
Vascular dementia (n = 15)
HR (95% CI)a
Aβ1–38 1.33 (1.01–1.89)b 1.39 (1.00–2.16)b 1.20 (0.49–2.96)
Aβ1–40 0.99 (0.69–1.43) 0.95 (0.60–1.49) 0.74 (0.31–1.79)
Aβ1–42 1.27 (1.02–1.58)b 1.35 (1.05–1.75)b 1.05 (0.61–1.79)
Aβ1–40/Aβ1–42 ratio 0.92 (0.64–1.32) 0.97 (0.64–1.49) 1.30 (0.54–3.11)
Abbreviations: Aβ amyloid-β, SD standard deviation, HR hazard ratio, CI confidence interval
aAdjusted for age, sex, education, mean arterial blood pressure, total cholesterol, diabetes, apolipoprotein ε4 carrier status, smoking and other Aβ levels
bSignificant at p <0.05
Table 4 Association of amyloid-β levels with incident dementia in carriers and non-carriers of apolipoprotein ε4 allele
Plasma Aβ levels
(per SD increase)
Incident dementia (n = 79)
HR (95% CI)a
APOE-ε4 carriers (n = 35) APOE-ε4 non-carriers (n = 44)
Aβ1–38 1.58 (1.01–2.89)b 1.10 (0.66–1.83)
Aβ1–40 1.03 (0.58–1.83) 1.04 (0.64–1.71)
Aβ1–42 1.07 (0.76–1.52) 1.47 (1.09–1.99)
b
Aβ1–40/Aβ1–42 ratio 0.72 (0.41–1.26) 0.75 (0.45–1.16)
Abbreviations: Aβ amyloid-β, SD standard deviation, HR hazard ratio, CI confidence interval, APOE Apolipoprotein
a Adjusted for age, sex, education, mean arterial blood pressure, total cholesterol, diabetes, smoking and other Aβ levels
bSignificant at p <0.05
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and persons with subjective cognitive complaints reported
greater cortical thickness at intermediate levels of Aβ
pathology (measured using CSF) [29]. By contrast, our
data suggest that lower plasma Aβ levels (which are
thought to indirectly reflect accumulation of amyloid in
brain) do not necessarily correlate with universal volumet-
ric decline in all structures (gray matter and white matter
volumes), which is supported by some recent data [30].
Several lines of evidence suggest that Aβ levels in the
CSF and plasma are in dynamic equilibrium with each
other and that increased Aβ production in the brain gives
rise to raised levels in the plasma [31]. It is further reported
that as Aβ starts to deposit in the brain in the form of pla-
ques, this in turn leads to lower plasma Aβ levels, which
has been related to a higher risk of dementia [32]. Previous
cross-sectional studies examining the association between
Aβ levels and dementia have been mainly inconsistent
[33–36]. It has been further reported that because plasma
Aβ levels tend to change over the course of the dementia
process, longitudinal studies are more useful in assessing
the link between Aβ levels and risk of dementia in asymp-
tomatic individuals [7]. Thus far, limited data have shown
that plasma Aβ1–42 levels significantly decline in concen-
tration in persons with newly diagnosed AD compared
with individuals with prevalent AD and control subjects
[12]. It is also suggested that plasma Aβ1–42 levels decline
at an average rate of 12% per year among individuals with
mild cognitive impairment [6]. Our results add to the pre-
vious reports by showing that lower levels of baseline
plasma Aβ1–38, in addition to Aβ1–40 and Aβ1–42, were
associated with a reduced risk of dementia. The associ-
ation of Aβ1–38 and Aβ1–42 with dementia persisted when
all the isoforms were added together in the model, indicat-
ing an independent link with increased dementia risk.
These observations further support the findings that Aβ1–38
and Aβ1–42 may be generated independently by γ-secretase
and that the production of these peptides is not coordi-
nately regulated [16]. This was further confirmed in in vitro
experiments involving γ-secretase modulators (sulindac sul-
fide), where Aβ1–38 levels were increased upon treatment
with sulindac sulfide with no concurrent effect on Aβ1–42
levels, thus arguing against a precursor–product relation-
ship [37, 38]. Though no association was observed between
Aβ1–38 levels and neurodegenerative markers in this study,
a link was still observed between lower levels of Aβ1–38 and
increased risk of dementia. As mentioned before, the
Aβ1–38 isoform is a marker of vascular pathology, and a
higher level may indicate the activation of different
inflammatory cascades (cytokines, cluster of differenti-
ation 40 ligand, and tumor necrosis factor α) [22],
which may increase the vulnerability to dementia, but
such a relationship requires further clarification. More-
over, the relationship of plasma Aβ levels and brain
amyloid deposition is suggested to be further
complicated by dynamics of the blood-brain barrier and
other possible sources of Aβ materials outside the cen-
tral nervous system, including platelets and skeletal
muscle cells [32].
With respect to the subtypes of dementia, similar associ-
ations were observed between plasma Aβ1–38 and Aβ1–42
levels with AD and vascular dementia. Though the signifi-
cant results were observed only in cases of AD, this finding
might be related to the fact that most of the individuals
diagnosed with incident dementia had AD (72%). Also, in
an elderly population, mixed pathology is commonly
observed, which might explain the similar estimates for
AD and vascular dementia. Moreover, the association of
lower levels of Aβ1–38 with increased risk of dementia was
more significant in carriers of the APOE-ε4 allele than in
noncarriers. Though an opposite link was observed
between Aβ1–42 and increased dementia risk in APOE-ε4
noncarriers, the similarity in the direction of effect esti-
mates further suggests a role of mixed pathology in the de-
velopment of dementia, regardless of APOE carrier status.
Strengths of our study include its prospective design, the
population-based setting, volumetric quantification of the
brain tissues, and virtually complete follow-up for demen-
tia in the older cohort. There are some potential limitations
of our study. First, because plasma samples were collected
after MRI acquisition with a 3-year time window, the effect
estimates calculated in this study may represent over- or
underestimations. Second, plasma Aβ levels provide an
indirect measure of brain-specific Aβ pathology, and an in
vivo analysis of brain-specific Aβ burden (such as with
amyloid positron emission tomography) could allow more
accurate measures of Aβ burden. Finally, we lacked
repeated measurement of plasma Aβ concentrations,
which limits its ability to better estimate the trajectory of
plasma levels over time in relation to risk of dementia.
However, this could be a subject for further studies.
Conclusions
This study provides evidence that lower plasma Aβ levels,
specifically Aβ1–38 and Aβ1–42, are associated with
increased risk of dementia, specifically AD. Future studies
should examine whether inclusion of novel plasma Aβ1–38
levels as an additional biomarker can provide further infor-
mation on risk of developing dementia and AD dementia.
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